A Phase 3 interventional study of DLBS3233 and Metformin XR in Polycystic Ovary Syndrome (PCOS), sponsored by Dexa Medica Group. Completed at 2 sites in Indonesia. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2018-07-26.
Sponsored by Dexa Medica Group · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a 2-arm, randomized, double-blind, double-dummy, and controlled clinical study, with 6 months of treatment to evaluate the clinical and metabolic efficacy of DLBS3233 in improving reproductive parameters and to evaluate the safety of DLBS3233 in women with polycystic ovary syndrome compared with metformin, as an active control.
There will be 2 groups of treatment; each group will consist of 62 subjects with the treatment regimens :
Clinical examination to evaluate the efficacy of the investigational drug will be performed at baseline and every interval of 1 month.
Laboratory examinations to evaluate the metabolic efficacy parameters and ultrasonography (USG) examination will be performed at baseline, Month 3rd, and end of study (Month 6th). In addition to that, USG will also be performed about 2 weeks after Month 3rd (Month 3.5th) and after Month 5th (Month 5.5th).
Laboratory examinations to evaluate the reproductive efficacy parameters (reproductive hormone levels) and safety, at baseline and Month 6th (end of study).
General counseling on lifestyle modification will be provided to the subjects by the assigned Nutritionist. All study subjects should follow a lifestyle modification. Evaluation on subjects' performance on lifestyle modification will be conducted every follow-up visit by Investigator, but particularly at baseline, Month 3rd, and end of study (Month 6th) by the Nutritionist.
958 studies on the registry are indexed under Polycystic Ovary Syndrome; 176 are open to participants now.
This study's enrollment of 124 is above the median of 70 across 699 interventional studies indexed under Polycystic Ovary Syndrome.
Browse Polycystic Ovary Syndrome studies →Dexa Medica Group is the lead sponsor of 44 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1 DLBS3233 capsule 100 mg (once daily) and 1 placebo caplet of Metformin XR (twice daily)
Drug: DLBS3233 · Drug: Placebo caplet of Metformin XR
1 Metformin XR caplet 750 mg (twice daily) and 1 placebo capsule of DLBS3233 (once daily)
Drug: Metformin XR · Drug: Placebo capsule of DLBS3233
1 DLBS3233 capsule 100 mg once daily for 6 months
Also known as: Inlacin
1 Metformin XR caplet 750 mg twice daily for 6 months
Also known as: Glumin XR
1 placebo caplet of Metformin XR twice daily for 6 months
Also known as: Placebo caplet of Glumin XR
1 placebo capsule of DLBS3233 once daily for 6 months
Also known as: Placebo capsule of Inlacin
HOMA-IR reduction
HOMA-IR reduction from baseline to Month 6th (end of study)
Time frame: 6 months
Reduction of S/A ratio
Reduction (indicating improvement) of S/A ratio (i.e. ratio of mean stromal echogenicity to mean echogenicity of entire ovary) from baseline to Month 3rd and Month 6th (end of study)
Time frame: 3 and 6 months
Reduction of free testosterone level (calculated)
Reduction of free testosterone level (calculated) from baseline to Month 6th (end of study)
Time frame: 6 months
Change of luteinizing hormone (LH) level
Change of luteinizing hormone (LH) level from baseline to Month 6th (end of study)
Time frame: 6 months
Change of luteinizing hormone (LH) / follicle stimulating hormone (FSH) ratio
Change of luteinizing hormone (LH) / follicle stimulating hormone (FSH) ratio from baseline to Month 6th (end of study)
Time frame: 6 months
Change of Ferriman-Gallwey Score
Change of Ferriman-Gallwey Score from baseline to Month 3rd and Month 6th (end of study)
Time frame: 3 and 6 months
Improvement of glucose tolerance
Improvement of glucose tolerance (reduction of FPG and 2-hour PPPG) from baseline to Month 3rd and Month 6th (end of study)
Time frame: 3 and 6 months
Fasting insulin level reduction
Fasting insulin level reduction from baseline to Month 3rd and Month 6th (end of study)
Time frame: 3 and 6 months
HOMA-IR reduction
HOMA-IR reduction from baseline to Month 3rd
Time frame: 3 months
Lipid profile improvement
Lipid profile improvement (total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides level) from baseline to Month 3rd and Month 6th (end of study)
Time frame: 3 and 6 months
Liver function
Liver function (serum AST, ALT, alkaline phosphatase, γ-glutamyl transferase) from baseline to Month 6th (end of study)
Time frame: 6 months
Renal function
Renal function (serum creatinine, BUN) from baseline to Month 6th (end of study)
Time frame: 6 months
Number of adverse events and subjects with events
Adverse events as well as number of events and subjects experiencing the events will be observed and evaluated throughout study period (6 months) and until all adverse events have been recovered or stabilized
Time frame: During 6 months
The record gives a start of Mar 2013, a primary completion of Apr 2018 and a completion of Jun 2018. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: DLBS3233